262 related articles for article (PubMed ID: 31817643)
1. B-RAF
Sugaya T; Kanno H; Matsuda M; Handa K; Tateda S; Murakami T; Ozawa H; Itoi E
Cells; 2019 Dec; 8(12):. PubMed ID: 31817643
[TBL] [Abstract][Full Text] [Related]
2. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury.
Li JX; Feng JM; Wang Y; Li XH; Chen XX; Su Y; Shen YY; Chen Y; Xiong B; Yang CH; Ding J; Miao ZH
Cell Death Dis; 2014 Jun; 5(6):e1278. PubMed ID: 24901049
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal damage after spinal cord injury causes accumulation of RIPK1 and RIPK3 proteins and potentiation of necroptosis.
Liu S; Li Y; Choi HMC; Sarkar C; Koh EY; Wu J; Lipinski MM
Cell Death Dis; 2018 May; 9(5):476. PubMed ID: 29686269
[TBL] [Abstract][Full Text] [Related]
4. GDF-11 Protects the Traumatically Injured Spinal Cord by Suppressing Pyroptosis and Necroptosis via TFE3-Mediated Autophagy Augmentation.
Xu Y; Hu X; Li F; Zhang H; Lou J; Wang X; Wang H; Yin L; Ni W; Kong J; Wang X; Li Y; Zhou K; Xu H
Oxid Med Cell Longev; 2021; 2021():8186877. PubMed ID: 34712387
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of PSMB4 is Associated with the Necroptosis after Spinal Cord Injury.
Wu C; Chen J; Liu Y; Zhang J; Ding W; Wang S; Bao G; Xu G; Sun Y; Wang L; Chen L; Gu H; Cui B; Cui Z
Neurochem Res; 2016 Nov; 41(11):3103-3112. PubMed ID: 27514644
[TBL] [Abstract][Full Text] [Related]
6. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
7. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Neural Stem Cell Necroptosis Mediated by RIPK1/MLKL Promotes Functional Recovery After SCI.
Tong K; Li S; Chen G; Ma C; Liu X; Liu S; Chen N
Mol Neurobiol; 2023 Apr; 60(4):2135-2149. PubMed ID: 36602703
[TBL] [Abstract][Full Text] [Related]
9. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma.
Geserick P; Wang J; Schilling R; Horn S; Harris PA; Bertin J; Gough PJ; Feoktistova M; Leverkus M
Cell Death Dis; 2015 Sep; 6(9):e1884. PubMed ID: 26355347
[TBL] [Abstract][Full Text] [Related]
10. Low-energy extracorporeal shock wave therapy promotes vascular endothelial growth factor expression and improves locomotor recovery after spinal cord injury.
Yamaya S; Ozawa H; Kanno H; Kishimoto KN; Sekiguchi A; Tateda S; Yahata K; Ito K; Shimokawa H; Itoi E
J Neurosurg; 2014 Dec; 121(6):1514-25. PubMed ID: 25280090
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of melatonin on necroptosis via repressing the Ripk3-PGAM5-CypD-mPTP pathway attenuates cardiac microvascular ischemia-reperfusion injury.
Zhou H; Li D; Zhu P; Ma Q; Toan S; Wang J; Hu S; Chen Y; Zhang Y
J Pineal Res; 2018 Oct; 65(3):e12503. PubMed ID: 29770487
[TBL] [Abstract][Full Text] [Related]
12. Dabrafenib in the treatment of advanced melanoma.
Medina T; Amaria MN; Jimeno A
Drugs Today (Barc); 2013 Jun; 49(6):377-85. PubMed ID: 23807941
[TBL] [Abstract][Full Text] [Related]
13. High glucose-induced apoptosis and necroptosis in podocytes is regulated by UCHL1 via RIPK1/RIPK3 pathway.
Xu Y; Gao H; Hu Y; Fang Y; Qi C; Huang J; Cai X; Wu H; Ding X; Zhang Z
Exp Cell Res; 2019 Sep; 382(2):111463. PubMed ID: 31247189
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of the receptor-interacting protein 3 expression and involvement in neural tissue damage after spinal cord injury in mice.
Kanno H; Ozawa H; Tateda S; Yahata K; Itoi E
BMC Neurosci; 2015 Oct; 16():62. PubMed ID: 26450067
[TBL] [Abstract][Full Text] [Related]
15. Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation.
Verschelden G; Van Laethem J; Velkeniers B; Ilsen B; Noeparast A; De Grève J
Pol Arch Intern Med; 2018 Jun; 128(6):386-388. PubMed ID: 29968698
[No Abstract] [Full Text] [Related]
16. RIPK3 blockade attenuates tubulointerstitial fibrosis in a mouse model of diabetic nephropathy.
Shi Y; Huang C; Zhao Y; Cao Q; Yi H; Chen X; Pollock C
Sci Rep; 2020 Jun; 10(1):10458. PubMed ID: 32591618
[TBL] [Abstract][Full Text] [Related]
17. BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.
Najafov A; Zervantonakis IK; Mookhtiar AK; Greninger P; March RJ; Egan RK; Luu HS; Stover DG; Matulonis UA; Benes CH; Yuan J
PLoS Biol; 2018 Aug; 16(8):e2005756. PubMed ID: 30157175
[TBL] [Abstract][Full Text] [Related]
18. The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
Qin X; Hu L; Shi SN; Chen X; Zhuang C; Zhang W; Jitkaew S; Pang X; Yu J; Tan YX; Wang HY; Cai Z
Biochem Pharmacol; 2020 Jul; 177():113947. PubMed ID: 32247850
[TBL] [Abstract][Full Text] [Related]
19. [Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Heneberg P
Klin Onkol; 2012; 25(5):333-9. PubMed ID: 23102194
[TBL] [Abstract][Full Text] [Related]
20. RIPK3 blockade attenuates kidney fibrosis in a folic acid model of renal injury.
Shi Y; Huang C; Yi H; Cao Q; Zhao Y; Chen J; Chen X; Pollock C
FASEB J; 2020 Aug; 34(8):10286-10298. PubMed ID: 32542792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
